bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
Published 9 months ago • 586 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
1:44
predicting thrombocytopenia as a result of ruxolitinib treatment in mf
-
3:46
a phase ib/ii trial of sonrotoclax plus dexamethasone in patients with r/r mm harboring t(11;14)
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:58
transform-1: navitoclax ruxolitinib vs placebo ruxolitinib in patients with untreated mf
-
1:38
the use of golcadomide in combination with r-chop for the treatment of aggressive b-cell lymphomas
-
6:14
il-23 blockade with guselkumab potentially modifies psoriasis pathogenesis
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
1:02
dreamm-3: safety of belantamab mafodotin versus pom/dex in patients with r/r myeloma
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
3:51
an update on the use of fmt for the treatment of steroid- and ruxolitinib-resistant acute gvhd
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml
-
1:38
a phase i study of wvt078, a bcma×cd3 bsab, with a gamma-secretase inhibitor (whg626) in r/r mm
-
2:22
dreamm-5 sub-study: belamaf in combination with feladilimab in the treatment of r/r myeloma
-
14:38
hematology in 10 min hemostasis and coagulation mp4 final
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study